Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 1
1999 1
2002 1
2004 1
2005 8
2006 11
2007 20
2008 23
2009 20
2010 23
2011 24
2012 27
2013 25
2014 37
2015 36
2016 26
2017 14
2018 22
2019 23
2020 31
2021 30
2022 19
2023 22
2024 25
2025 29
2026 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

468 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal beta-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.
Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, Archuleta S, Roberts MA, Cass A, Paterson DL, Foo H, Paul M, Guy SD, Tramontana AR, Walls GB, McBride S, Bak N, Ghosh N, Rogers BA, Ralph AP, Davies J, Ferguson PE, Dotel R, McKew GL, Gray TJ, Holmes NE, Smith S, Warner MS, Kalimuddin S, Young BE, Runnegar N, Andresen DN, Anagnostou NA, Johnson SA, Chatfield MD, Cheng AC, Fowler VG Jr, Howden BP, Meagher N, Price DJ, van Hal SJ, O'Sullivan MVN, Davis JS; Australasian Society for Infectious Diseases Clinical Research Network. Tong SYC, et al. JAMA. 2020 Feb 11;323(6):527-537. doi: 10.1001/jama.2020.0103. JAMA. 2020. PMID: 32044943 Free PMC article. Clinical Trial.
IMPORTANCE: Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with mortality of more than 20%. ...CONCLUSIONS AND RELEVANCE: Among patients with MRSA bacteremia, addition of an antistaphylococcal be …
IMPORTANCE: Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with morta …
Management of Staphylococcus aureus Bacteremia: A Review.
Tong SYC, Fowler VG Jr, Skalla L, Holland TL. Tong SYC, et al. JAMA. 2025 Sep 2;334(9):798-808. doi: 10.1001/jama.2025.4288. JAMA. 2025. PMID: 40193249 Free PMC article. Review.
Other imaging modalities, such as computed tomography or magnetic resonance imaging, should be performed based on symptoms and localizing signs of metastatic infection. Staphylococcus aureus is categorized as methicillin-susceptible (MSSA) or methicillin-r …
Other imaging modalities, such as computed tomography or magnetic resonance imaging, should be performed based on symptoms and localizing si …
Effectiveness and Safety of Linezolid Versus Vancomycin, Teicoplanin, or Daptomycin against Methicillin-Resistant Staphylococcus aureus Bacteremia: A Systematic Review and Meta-Analysis.
Kawasuji H, Nagaoka K, Tsuji Y, Kimoto K, Takegoshi Y, Kaneda M, Murai Y, Karaushi H, Mitsutake K, Yamamoto Y. Kawasuji H, et al. Antibiotics (Basel). 2023 Apr 2;12(4):697. doi: 10.3390/antibiotics12040697. Antibiotics (Basel). 2023. PMID: 37107059 Free PMC article. Review.
Vancomycin (VCM) and daptomycin (DAP) are standard therapies for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, despite concerns regarding clinical utility and growing resistance. Linezolid (LZD) affords superior ti …
Vancomycin (VCM) and daptomycin (DAP) are standard therapies for methicillin-resistant Staphylococcus aureus …
Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial.
Turner NA, Hamasaki T, Doernberg SB, Lodise TP, King HA, Ghazaryan V, Cosgrove SE, Jenkins TC, Liu C, Sharma S, Zaharoff S, Wahid L, Renard VJ, Cook P, Raad I, Hachem R, Chaftari AM, Sims M, DeMarco C, Miller LG, McCarthy MW, Morse CG, Lucasti C, Forrest GN, Cherabuddi K, Polk C, Fazili T, Rupp ME, Thompson GR 3rd, Kim K, Strnad L, Schnee AE, McKinnell JA, Ramesh M, Silveira FP, McCarty TP, Lee TC, McDonald EG, Paolino K, Wiegand K, Wall A, Riccobene T, Patel R, Rappo U, Evans S, Chambers HF, Fowler VG Jr, Holland TL; Antibacterial Resistance Leadership Group. Turner NA, et al. JAMA. 2025 Aug 13;334(10):866-77. doi: 10.1001/jama.2025.12543. Online ahead of print. JAMA. 2025. PMID: 40802264 Free PMC article.
IMPORTANCE: Dalbavancin is a long-acting intravenous lipoglycopeptide that may be effective for treatment of complicated Staphylococcus aureus bacteremia without requiring long-term intravenous access. OBJECTIVE: To evaluate the efficacy and safety of dalbava …
IMPORTANCE: Dalbavancin is a long-acting intravenous lipoglycopeptide that may be effective for treatment of complicated Staphylococcus …
Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.
Geriak M, Haddad F, Rizvi K, Rose W, Kullar R, LaPlante K, Yu M, Vasina L, Ouellette K, Zervos M, Nizet V, Sakoulas G. Geriak M, et al. Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02483-18. doi: 10.1128/AAC.02483-18. Print 2019 May. Antimicrob Agents Chemother. 2019. PMID: 30858203 Free PMC article. Clinical Trial.
Vancomycin (VAN) and daptomycin (DAP) are approved as a monotherapy for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. A regimen of daptomycin plus ceftaroline (DAP+CPT) has shown promise in published case se …
Vancomycin (VAN) and daptomycin (DAP) are approved as a monotherapy for methicillin-resistant Staphylococcus …
Update on Staphylococcus aureus bacteraemia.
Tabah A, Laupland KB. Tabah A, et al. Curr Opin Crit Care. 2022 Oct 1;28(5):495-504. doi: 10.1097/MCC.0000000000000974. Epub 2022 Aug 4. Curr Opin Crit Care. 2022. PMID: 35942696 Review.
PURPOSE OF REVIEW: To review recently published evidence relevant to Staphylococcus aureus bacteremia (SAB). RECENT FINDINGS: Staphylococcus aureus is the most common pathogen causing co-infections and superinfections in patients with COVID-19. …
PURPOSE OF REVIEW: To review recently published evidence relevant to Staphylococcus aureus bacteremia (SAB). RECENT FIN …
Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.
Holland TL, Cosgrove SE, Doernberg SB, Jenkins TC, Turner NA, Boucher HW, Pavlov O, Titov I, Kosulnykov S, Atanasov B, Poromanski I, Makhviladze M, Anderzhanova A, Stryjewski ME, Assadi Gehr M, Engelhardt M, Hamed K, Ionescu D, Jones M, Saulay M, Smart J, Seifert H, Fowler VG Jr; ERADICATE Study Group. Holland TL, et al. N Engl J Med. 2023 Oct 12;389(15):1390-1401. doi: 10.1056/NEJMoa2300220. Epub 2023 Sep 27. N Engl J Med. 2023. PMID: 37754204 Free article. Clinical Trial.
BACKGROUND: Ceftobiprole is a cephalosporin that may be effective for treating complicated Staphylococcus aureus bacteremia, including methicillin-resistant S. aureus. METHODS: In this phase 3, double-blind, double-dummy, noninferiority t …
BACKGROUND: Ceftobiprole is a cephalosporin that may be effective for treating complicated Staphylococcus aureus bacteremia …
Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial.
Pujol M, Miró JM, Shaw E, Aguado JM, San-Juan R, Puig-Asensio M, Pigrau C, Calbo E, Montejo M, Rodriguez-Álvarez R, Garcia-Pais MJ, Pintado V, Escudero-Sánchez R, Lopez-Contreras J, Morata L, Montero M, Andrés M, Pasquau J, Arenas MD, Padilla B, Murillas J, Jover-Sáenz A, López-Cortes LE, García-Pardo G, Gasch O, Videla S, Hereu P, Tebé C, Pallarès N, Sanllorente M, Domínguez MÁ, Càmara J, Ferrer A, Padullés A, Cuervo G, Carratalà J; MRSA Bacteremia (BACSARM) Trial Investigators. Pujol M, et al. Clin Infect Dis. 2021 May 4;72(9):1517-1525. doi: 10.1093/cid/ciaa1081. Clin Infect Dis. 2021. PMID: 32725216 Free PMC article. Clinical Trial.
BACKGROUND: We aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than daptomycin alone for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis. METHODS: A rand …
BACKGROUND: We aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than daptomycin alone f …
Clinical management of Staphylococcus aureus bacteremia: a review.
Holland TL, Arnold C, Fowler VG Jr. Holland TL, et al. JAMA. 2014 Oct 1;312(13):1330-41. doi: 10.1001/jama.2014.9743. JAMA. 2014. PMID: 25268440 Free PMC article. Review.
IMPORTANCE: Several management strategies may improve outcomes in patients with Staphylococcus aureus bacteremia. OBJECTIVES: To review evidence of management strategies for S. aureus bacteremia to determine whether transesophageal echocardiogra …
IMPORTANCE: Several management strategies may improve outcomes in patients with Staphylococcus aureus bacteremia. OBJEC …
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE; S. aureus Endocarditis and Bacteremia Study Group. Fowler VG Jr, et al. N Engl J Med. 2006 Aug 17;355(7):653-65. doi: 10.1056/NEJMoa053783. N Engl J Med. 2006. PMID: 16914701 Free article. Clinical Trial.
BACKGROUND: Alternative therapies for Staphylococcus aureus bacteremia and endocarditis are needed. METHODS: We randomly assigned 124 patients with S. aureus bacteremia with or without endocarditis to receive 6 mg of daptomycin intravenou …
BACKGROUND: Alternative therapies for Staphylococcus aureus bacteremia and endocarditis are needed. METHODS: We randoml …
468 results